DARPin technology functions by utilizing custom-engineered binding proteins designed to mimic or augment the target-recognition capabilities of natural antibodies while offering superior structural stability. Researchers take non-antibody ankyrin repeat scaffold proteins and randomize specific amino acid residues located on their exposed outer interaction surfaces. Using high-throughput in vitro selection methods like ribosome display, vast libraries of these proteins are screened to isolate specific variants that bind tightly and selectively to disease-associated targets, such as viral surface proteins or tumor receptors, thereby neutralizing pathogens or blocking pathological signaling pathways.